Booking.com

Targovax selected for oral presentation at Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting

Booking.com

Oslo, Norway, 9 October 2019 – Targovax ASA (OSE: TRVX), announces that clinical data on the company’s lead product candidate ONCOS-102, a genetically modified oncolytic adenovirus which has been engineered to selectively infect and replicate in cancer cells, will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting being held November 6-10, 2019, in Maryland, USA.
Title: A pilot study of engineered adenovirus ONCOS-102 in combination
with pembrolizumab in checkpoint inhibitor refractory advanced or
unresectable melanoma
Authors:

Source: Targovax selected for oral presentation at Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting

Booking.com
Booking.com

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.